PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.
about
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasisPPARs and the cardiovascular systemThe peroxisome proliferator activated receptor delta is required for the differentiation of THP-1 monocytic cells by phorbol esterActivation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation.Inflammation, obesity, and thrombosisFenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewEmerging therapeutic targets of sepsis-associated acute kidney injury.The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective.Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophagesActivated Monocytes Enhance Platelet-Driven Contraction of Blood Clots via Tissue Factor ExpressionL-carnitine protects against carboplatin-mediated renal injury: AMPK- and PPARα-dependent inactivation of NFAT3.The Role of PPARα Activation in Liver and Muscle.Stabilization of atherosclerotic plaques: new mechanisms and clinical targets.PPAR-alpha effects on the heart and other vascular tissues.Tissue factor, blood coagulation, and beyond: an overview.Peroxisome proliferator-activated receptor ligands in atherosclerosis.Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications.PPARalpha in atherosclerosis and inflammation.Pleiotropic effects of fibrates.Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.Recent findings concerning thiazolidinediones in the treatment of diabetes.Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.PPARs and molecular mechanisms of transrepressionVascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.Peroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular systemModulation of endothelial cell thrombomodulin by PPAR ligands--variation according to environment.Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?Nuclear receptors and inflammatory diseases.Molecular mechanisms involved in NAFLD progression.Influence of conjugated linoleic acids on functional properties of vascular cells.HDL inflammation and atherosclerosis: current and future perspectives.Peroxisome proliferator-activated receptors and atherosclerosis.Therapeutic Potential of PPARγ Activation in Stroke.The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes.PPARα as a therapeutic target in inflammation-associated diseases.Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists
P2860
Q24541529-6E474533-AEB1-4B54-97D6-59F7130131A9Q24642728-AE15B561-8AA1-407D-AF8B-BAEC1A1F2312Q24806798-83138E6C-5039-45DE-90F8-44F1340BBF6FQ24806958-AEC38F43-C761-4926-96CE-811851E090CDQ27008937-889CF884-DFA5-49BC-81F7-F5E44B8A7303Q28220294-FFB1A02C-6915-40FB-AE80-E05C52711D1BQ30300333-51802743-A3B7-4FB7-BAED-C34B4F8A323AQ30357715-9B58918B-F911-4399-AB96-B145F49F44C8Q33306319-BE45B5B5-BD1E-479C-869E-FA16D7036773Q33870766-09BD2643-4F82-43BE-AFC4-2DD8363A2F4EQ33894973-C9FCD3D5-F7D4-46A9-8345-C3665F79FD16Q34000195-58DC0DB6-7340-4FCA-BF66-2F821FE5006FQ34106233-CE8D7BC4-69AE-46C3-8E2C-201C00DF6DB9Q34986368-638BCA74-AD52-4234-8027-9DF3CAB6D4F5Q35080447-1FBDE930-803B-4B0F-BD46-FBD1CBCEBF26Q35222618-A493C225-93DA-4B4A-9708-1502AA423EB1Q35925566-27230C86-A8B4-4A44-BA16-BBFA46298A4BQ35940672-FF1E501A-08D4-4959-AEFD-D5DCF4A6A020Q36154953-528818D7-7B81-4D38-8CCA-03A0F111A784Q36232396-6BB931F7-5546-4FCF-99CC-EB076C28CE97Q36401585-C870DA11-ADF4-49C5-8438-C7B9FA129FB0Q36407304-015DA5FF-13B7-4FEB-AFDD-A15ECB9261A0Q36438737-38476AB5-DE1B-4586-9DC7-0A8DC54880B8Q36580568-C69784DB-C676-4488-9DC4-E50A7F1E3C7DQ36791361-EC6712B6-9D5D-416A-B128-A6597CF32BC6Q36894180-AD58A7D6-E261-4D65-BB46-9F516565ABB0Q36952106-5C2DF890-2713-4473-8007-1390119A86B8Q36960958-3DE5A90F-5BB2-43F9-935D-B17779CD09F2Q36992256-A14FC877-20C3-4479-B5A9-61259CDDABA6Q37016305-0CD70FBD-E654-4112-BD1E-DF874949F091Q37119252-946DA0F1-7BB2-47B8-8617-78217D1CDF6EQ37122891-6B664F3B-A1B8-440B-8DD1-08C49B660D1CQ37437295-534D8311-8D4E-44CE-BB1B-FC56C336F06AQ37557746-C32190CE-3DD3-4FA7-9EB2-E9B40C14C8C5Q37608502-B314E5F2-3C4A-43DE-AEC5-4786B795B5B0Q37861955-15417E64-71DD-4477-B300-BE1559AA44EDQ37930425-42E162A9-D39C-4C72-A574-AC7912FB7EACQ37997004-350D7202-CF73-4DF4-8F53-E0C5E86F7826Q38038289-C8438F07-41B0-40AC-8E77-9D3F5D0A4938Q38110581-711D50A8-DBE2-4879-A2A6-53485968FD4A
P2860
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.
@ast
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.
@en
type
label
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.
@ast
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.
@en
prefLabel
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.
@ast
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.
@en
P2093
P356
P1433
P1476
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.
@en
P2093
Chinetti G
Corseaux D
Fruchart JC
Zawadzki C
P304
P356
10.1161/01.CIR.103.2.207
P407
P577
2001-01-01T00:00:00Z